160 related articles for article (PubMed ID: 37673640)
1. Sodium-glucose cotransporter-2 inhibitors increase urinary tract infections?-a cross sectional analysis of a nationwide Japanese claims database.
Anan G; Kikuchi D; Omae K; Hirose T; Okada K; Mori T
Endocr J; 2023 Nov; 70(11):1103-1107. PubMed ID: 37673640
[TBL] [Abstract][Full Text] [Related]
2. Sodium-Glucose Cotransporter-2 Inhibitors and Urinary Tract Infections: A Propensity Score-matched Population-based Cohort Study.
Alkabbani W; Zongo A; Minhas-Sandhu JK; Eurich DT; Shah BR; Alsabbagh MW; Gamble JM
Can J Diabetes; 2022 Jun; 46(4):392-403.e13. PubMed ID: 35513988
[TBL] [Abstract][Full Text] [Related]
3. Sodium-glucose cotransporter-2 inhibitors and the risk of urinary tract infection among diabetic patients in Japan: Target trial emulation using a nationwide administrative claims database.
Takeuchi Y; Kumamaru H; Hagiwara Y; Matsui H; Yasunaga H; Miyata H; Matsuyama Y
Diabetes Obes Metab; 2021 Jun; 23(6):1379-1388. PubMed ID: 33606891
[TBL] [Abstract][Full Text] [Related]
4. Estimation of sodium-glucose cotransporter 2 inhibitor-related genital and urinary tract infections via electronic medical record-based common data model.
Ko S; Kim H; Shinn J; Byeon SJ; Choi JH; Kim HS
J Clin Pharm Ther; 2021 Aug; 46(4):975-983. PubMed ID: 33565150
[TBL] [Abstract][Full Text] [Related]
5. Effects of SGLT2 inhibitors on UTIs and genital infections in type 2 diabetes mellitus: a systematic review and meta-analysis.
Liu J; Li L; Li S; Jia P; Deng K; Chen W; Sun X
Sci Rep; 2017 Jun; 7(1):2824. PubMed ID: 28588220
[TBL] [Abstract][Full Text] [Related]
6. Sodium glucose cotransporter 2 inhibitors and risk of genital mycotic and urinary tract infection: A population-based study of older women and men with diabetes.
Lega IC; Bronskill SE; Campitelli MA; Guan J; Stall NM; Lam K; McCarthy LM; Gruneir A; Rochon PA
Diabetes Obes Metab; 2019 Nov; 21(11):2394-2404. PubMed ID: 31264755
[TBL] [Abstract][Full Text] [Related]
7. Acute Renal Failure, Ketoacidosis, and Urogenital Tract Infections with SGLT2 Inhibitors: Signal Detection Using a Japanese Spontaneous Reporting Database.
Katsuhara Y; Ogawa T
Clin Drug Investig; 2020 Jul; 40(7):645-652. PubMed ID: 32451843
[TBL] [Abstract][Full Text] [Related]
8. Contemporary use of SGLT2 inhibitors in heart failure patients with diabetes mellitus: a comparison of DPP4 inhibitors in a nationwide electric health database of the superaged society.
Nakai M; Iwanaga Y; Kanaoka K; Sumita Y; Nishioka Y; Myojin T; Kubo S; Okada K; Soeda T; Noda T; Sakata Y; Imamura T; Saito Y; Yasuda S; Miyamoto Y
Cardiovasc Diabetol; 2022 Aug; 21(1):157. PubMed ID: 35964039
[TBL] [Abstract][Full Text] [Related]
9. Urinary tract and genital infections in patients with type 2 diabetes treated with sodium-glucose co-transporter 2 inhibitors: A meta-analysis of randomized controlled trials.
Li D; Wang T; Shen S; Fang Z; Dong Y; Tang H
Diabetes Obes Metab; 2017 Mar; 19(3):348-355. PubMed ID: 27862830
[TBL] [Abstract][Full Text] [Related]
10. [Relative frequency of urinary tract infections in patients affected by diabetes mellitus type 2 treated with metformin and SGLT2 inhibitor.
Merész G; Szabó S; Dóczy V; Hölgyesi Á; Szakács Z
Orv Hetil; 2020 Mar; 161(13):491-501. PubMed ID: 32202151
[TBL] [Abstract][Full Text] [Related]
11. Urinary tract infection in randomized phase III studies of canagliflozin, a sodium glucose co-transporter 2 inhibitor.
Nicolle LE; Capuano G; Fung A; Usiskin K
Postgrad Med; 2014 Jan; 126(1):7-17. PubMed ID: 24393747
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of sodium-glucose cotransporter 2 inhibitors in type 2 diabetes: a meta-analysis of randomized controlled trials for 1 to 2years.
Liu XY; Zhang N; Chen R; Zhao JG; Yu P
J Diabetes Complications; 2015; 29(8):1295-303. PubMed ID: 26365905
[TBL] [Abstract][Full Text] [Related]
13. Use of SGLT2 inhibitors for diabetes and risk of infection: Analysis using general practice records from the NPS MedicineWise MedicineInsight program.
Gadzhanova S; Pratt N; Roughead E
Diabetes Res Clin Pract; 2017 Aug; 130():180-185. PubMed ID: 28646701
[TBL] [Abstract][Full Text] [Related]
14. Assessing the Risk for Gout With Sodium-Glucose Cotransporter-2 Inhibitors in Patients With Type 2 Diabetes: A Population-Based Cohort Study.
Fralick M; Chen SK; Patorno E; Kim SC
Ann Intern Med; 2020 Feb; 172(3):186-194. PubMed ID: 31931526
[TBL] [Abstract][Full Text] [Related]
15. Characterization of Risk Factors for Genitourinary Infections with Sodium-Glucose Cotransporter-2 Inhibitors.
Benjamin T; Schumacher C
Pharmacotherapy; 2020 Oct; 40(10):1002-1011. PubMed ID: 32866995
[TBL] [Abstract][Full Text] [Related]
16. Risk factors for COVID-19 case fatality rate in people with type 1 and type 2 diabetes mellitus: A nationwide retrospective cohort study of 235,248 patients in the Russian Federation.
Shestakova MV; Vikulova OK; Elfimova AR; Deviatkin AA; Dedov II; Mokrysheva NG
Front Endocrinol (Lausanne); 2022; 13():909874. PubMed ID: 36017317
[TBL] [Abstract][Full Text] [Related]
17. Age- and sex-specific risk of urogenital infections in patients with type 2 diabetes treated with sodium-glucose co-transporter 2 inhibitors: A population-based self-controlled case-series study.
Kang M; Heo KN; Ah YM; Yang BR; Lee JY
Maturitas; 2021 Aug; 150():30-36. PubMed ID: 34274073
[TBL] [Abstract][Full Text] [Related]
18. Impact of sodium-glucose cotransporter-2 inhibitors on the risk of hip fracture in older patients in Japan using a nationwide administrative claims database: A matched case-control study.
Saito T; Nojiri S; Kasai T; Hiratsuka Y; Ishijima M; Daida H
Geriatr Gerontol Int; 2023 Jun; 23(6):418-425. PubMed ID: 37139826
[TBL] [Abstract][Full Text] [Related]
19. Comparative effectiveness and safety of sodium-glucose cotransporter-2 inhibitors versus metformin in patients with type 2 diabetes: An observational study using data from routine care.
Fralick M; Schneeweiss S; Redelmeier DA; Razak F; Gomes T; Patorno E
Diabetes Obes Metab; 2021 Oct; 23(10):2320-2328. PubMed ID: 34169619
[TBL] [Abstract][Full Text] [Related]
20. Identification of subgroups of patients with type 2 diabetes with differences in renal function preservation, comparing patients receiving sodium-glucose co-transporter-2 inhibitors with those receiving dipeptidyl peptidase-4 inhibitors, using a supervised machine-learning algorithm (PROFILE study): A retrospective analysis of a Japanese commercial medical database.
Zhou FL; Watada H; Tajima Y; Berthelot M; Kang D; Esnault C; Shuto Y; Maegawa H; Koya D
Diabetes Obes Metab; 2019 Aug; 21(8):1925-1934. PubMed ID: 31050099
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
